Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ibogaine/Bipolar Disorder

Ibogaine for Bipolar Disorder

3 papers and 0 clinical trials exploring ibogaine as a treatment for bipolar disorder.

CompoundIndole Alkaloid

Ibogaine

A unique indole alkaloid with complex pharmacology, investigated primarily for its capacity to interrupt substance use disorders and withdrawal.

Full Ibogaine profile
Indication45 million worldwide

Bipolar Disorder

Bipolar disorder, characterised by extreme fluctuations in mood, is a complex mental health condition that affects approximately 45 million people worldwide. Current research on psychedelics as a potential treatment is limited due to concerns about inducing manic episodes, but emerging evidence, particularly regarding ketamine, suggests promise for alleviating depressive symptoms associated with the disorder.

Full Bipolar Disorder profile

Academic Research

3 papers
Open Accessindividual

Safety of ibogaine administration in detoxification of opioid dependent individuals: a descriptive open-label observational study

This open‑label study (n=14) of opioid‑dependent patients given a single 700 mg per 70kg dose of ibogaine‑HCl, treatment produced clinically relevant but reversible cardiac and cerebellar toxicity. The mean maximal QTc(F) prolongation was 95 ms, with 50% of participants exceeding 500 ms, accompanied by bradycardia and severe transient ataxia. Psychomimetic and withdrawal effects were generally manageable, and no torsades de pointes were observed.

Published
August 9, 2021
Journal
Addiction
Authors
Knuijver, T., Schellekens, A., Belgers, M., Donders, R., Kramers, C., Verkes, R. J.
Open Accessindividual

Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport

This study investigated serotonin transporter (SERT) complexes with ibogaine to illustrate structure-based mechanisms for transport in serotonin transporter (SERT). The investigation reported that cryo-electron microscopy structures of SERT-ibogaine complexes captured in outward-open, closed and inward-open conformations with ibogaine binding to the central binding site, and the closing extracellular gate with movements of TMs 1b and 6a. The intracellular gate opening had a hinge-like movement of TM1a and the partial unwinding of TM5 that together built a permeation pathway enabling substrate and ion diffusion to the cytoplasm. These structures show the structural rearrangements which occur from the outward-open to inward-open conformations, and give an important insight into the working mechanism of neurotransmitter transport and ibogaine inhibition.

Published
April 24, 2019
Journal
Nature
Authors
Coleman, J. A., Yang, D., Zhao, Z., Wen, P. C., Yoshioka, C., Gouaux, E.
Paywallindividual

Mania following use of ibogaine: A case series

This case report (n=3) examines patients who developed manic symptoms and diagnosed with Bipolar-I disorder in response to ibogaine use. None of the patients had a prior diagnosis or family history of bipolar disorder, but all of them were poly-drug users or recovering from addiction. Manic symptoms which often included grand delusions that lasted up to two weeks after using ibogaine.

Published
April 1, 2015
Journal
The American Journal on Addictions
Authors
Marta, C. J., Ryan, W. C., Kopelowicz, A., Koek, R. J.

Clinical Trials

0 trials

No clinical trials have been tagged with both Ibogaine and Bipolar Disorder yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Ibogaine papers Search all Bipolar Disorder trials Full Ibogaine profile Full Bipolar Disorder profile